Avanos Medical AVNS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $701.2M+1.9% | $687.8M+2.2% | $673.3M-6.8% | $722.2M+23.0% | ||
| $347.3M+13.3% | $306.5M+4.4% | $293.6M-5.6% | $310.9M+8.0% | ||
| $353.9M-7.2% | $381.3M+0.4% | $379.7M-7.7% | $411.3M+37.5% | ||
| 50.5%-5.0pp | 55.4%-1.0pp | 56.4%-0.6pp | 57%+6.0pp | ||
| $23.3M-11.1% | $26.2M-3.7% | $27.2M-8.4% | $29.7M-2.9% | ||
| $315.6M-0.9% | $318.5M-4.9% | $335M+1.4% | $330.3M+15.8% | ||
| -$64.1M+83.8% | -$396.2M-9,533% | $4.2M-91.3% | $48.1M+224% | ||
| -9.1%+48.5pp | -57.6%-58.2pp | 0.6%-6.0pp | 6.7%+13.3pp | ||
| $7.8M-36.1% | $12.2M-18.7% | $15M+50.0% | $10M+203% | ||
| —— | —— | —— | —— | ||
| -$67.4M+83.3% | -$403.3M— | —— | $39.3M+193% | ||
| $6.7M+139% | -$17M— | —— | $8.4M— | ||
| -$72.9M+81.4% | -$392.1M— | —— | $50.5M+702% | ||
| -10.4%+46.6pp | -57%— | —— | 7%+5.9pp | ||
| -$1.57+81.6% | -$8.53— | —— | $1.06+715% | ||
| -$25.2M+92.8% | -$350.7M-797% | $50.3M-47.5% | $95.8M+24,050% | ||
| -3.6%+47.4pp | -51%-58.5pp | 7.5%-5.8pp | 13.3%+13.3pp | ||
| -$64.1M+83.8% | -$396.2M-9,533% | $4.2M-91.3% | $48.1M+224% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Avanos Medical's revenue?
- Avanos Medical (AVNS) generated $715.9M in revenue over the trailing twelve months, up 3.9% year over year.
- Is Avanos Medical profitable?
- Avanos Medical is not currently profitable: it reported a net loss of $74.4M over the trailing twelve months, a -10.4% net margin.
- What are Avanos Medical's profit margins?
- Gross margin is 50.0% and operating margin is -9.1%, with a -10.4% net margin.
- What is Avanos Medical's earnings per share?
- Avanos Medical's diluted EPS over the trailing twelve months is $-1.60.
- Where does Avanos Medical's income statement data come from?
- Every line is extracted from Avanos Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
